Key Points
- CEO C. Randal Mills purchased 13,500 shares at $0.75 on Nov. 13 for $10,125, increasing his stake to 353,785 shares (a 3.97% boost).
- ELUT traded at $0.75 with heavy intraday volume (488,984 shares vs. avg. 102,372), a market cap of about $31.6M, and a 1‑year range of $0.69–$5.12.
- The company reported quarterly EPS of ($0.01), beating estimates of ($0.16) but missing revenue expectations ($3.32M vs. $6.65M); analysts are mixed with a consensus "Hold" and a $7.00 price target.
Elutia Inc. (NASDAQ:ELUT - Get Free Report) CEO C Randal Mills purchased 13,500 shares of Elutia stock in a transaction dated Thursday, November 13th. The shares were purchased at an average cost of $0.75 per share, for a total transaction of $10,125.00. Following the transaction, the chief executive officer owned 353,785 shares in the company, valued at approximately $265,338.75. This trade represents a 3.97% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Elutia Trading Up 0.3%
ELUT stock traded up $0.00 during midday trading on Friday, hitting $0.75. 488,984 shares of the company's stock were exchanged, compared to its average volume of 102,372. Elutia Inc. has a 1-year low of $0.69 and a 1-year high of $5.12. The stock has a market capitalization of $31.61 million, a PE ratio of -0.70 and a beta of 0.78. The business has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.64.
Elutia (NASDAQ:ELUT - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.15. The company had revenue of $3.32 million during the quarter, compared to analysts' expectations of $6.65 million. As a group, research analysts expect that Elutia Inc. will post -1.74 EPS for the current fiscal year.
Wall Street Analyst Weigh In
ELUT has been the subject of several research analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of Elutia in a research report on Wednesday, October 8th. Lake Street Capital dropped their price target on shares of Elutia from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, September 10th. Finally, Wall Street Zen upgraded Elutia to a "sell" rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.00.
Check Out Our Latest Analysis on Elutia
Institutional Trading of Elutia
Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in shares of Elutia in the 3rd quarter valued at about $26,000. Deerfield Management Company L.P. acquired a new position in Elutia in the third quarter valued at approximately $1,221,000. XTX Topco Ltd acquired a new position in Elutia in the second quarter valued at approximately $28,000. AIGH Capital Management LLC increased its stake in Elutia by 2.1% in the second quarter. AIGH Capital Management LLC now owns 3,451,025 shares of the company's stock valued at $6,833,000 after purchasing an additional 69,610 shares during the last quarter. Finally, Arcus Capital Partners LLC raised its holdings in Elutia by 50.3% during the second quarter. Arcus Capital Partners LLC now owns 30,050 shares of the company's stock worth $59,000 after purchasing an additional 10,050 shares in the last quarter. 74.03% of the stock is currently owned by institutional investors and hedge funds.
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
